Skip to content
Company Analysis

Supernus Pharmaceuticals, Inc. SUPN

A comprehensive view of key metrics, scores, and financial health for Supernus Pharmaceuticals, Inc.

Overview of Supernus Pharmaceuticals, Inc.

SUPN NGM
Healthcare Drug Manufacturers - Specialty & Generic Framework: Pharma / Mature Biotech Mid Cap
Supernus Pharmaceuticals, Inc. (SUPN), is a Mid Cap company, in the Drug Manufacturers - Specialty & Generic industry, last closed at $41.92, about 46.8% overvalued vs fair value, -11.3% 1Y return, ranked 442/1145 in sector.
Metrics Rev Growth 8.6% ROE -3.7% Gross Margin 89.6%
USD 41.92
0.00%
(Delayed)
• Vol 90d: 35.8%
52-Week Range
Market Cap
$2.44B
Enterprise Value
$2.26B
Overall Score
View breakdown
Overall
Growth
Fair
Profitability
Good
Health
Fair
Efficiency
Good
Valuation
Fair
Growth
Fair
Profitability
Good
Health
Fair
Efficiency
Good
Valuation
Fair
Completeness: 82%
Confidence: 90%
Updated: Oct 31
Top Beats

Quick Facts

Website https://www.supernus.com
HQ Rockville, MD
Employees 674
Fiscal year Dec 31

Next Events

No upcoming events available.

Fair Value Snapshot

Bear Base Bull
$20
$22
$25
Current: $41.92 -47% vs base

Engine Room Money Flow™

Mid Cap

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
$719.0M
8.6%%
Gross Profit
$644.4M
10.4%%
R&D Expense
$106.2M
-2.4%%
Operating Income (EBIT)
-$49.0M
-150.1%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Quality & Reliability Indicators

R&D Intensity
14.8%
Fair

Lower R&D intensity - may indicate mature portfolio or cost cuts

Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
3
Active Leaks
0/3
Improving
0
High Impact
3
Critical
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Supernus Pharmaceuticals, Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
55
/100
Moderate
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key strengths

  • Strong Interest Coverage & Conservative Leverage Debt serviceability is strong (score 0.79), with robust interest coverage.
  • Revenue Growth Consistent Revenue growth volatility is low (stability score 0.84), suggesting sticky customer base.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Moderate
52
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

vs Industry Peers 97% Coverage
Trade-Off Triangle Visualization A ternary plot showing SUPN's balance between Growth (28.4%), Profitability (31.6%), and Safety (40.0%). Growth 28% Safety 40% Profitability 32%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

47th percentile vs peers
47
Key Signals
Rev Growth YoY 8.6% 65p Revenue CAGR 3Y 2.5% 46p EPS CAGR 3Y 10.3% 63p EPS Growth YoY -1.52 10p
Strengths
  • Gross Profit Margin in top 20% of peers (89.6%, 90th percentile)
  • Net Debt/EBITDA in top 20% of peers (-3.02, 84th percentile)
  • Cash Flow to Debt Ratio in top 20% of peers (5.04, 91th percentile)
  • Conservative leverage compared to industry peers
Risks
  • EPS Growth YoY in bottom 20% of peers (-1.52)

Profitability

52th percentile vs peers
53
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

66th percentile vs peers
67
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Supernus Pharmaceuticals, Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$22.29
- - -
-46.8% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000